Business
Notice of Cipher Pharmaceuticals Q4 2019 Conference Call
Notice of Cipher Pharmaceuticals Q4 2019 Conference Call Canada NewsWire OAKVILL...
About this update from Cipher Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nNotice of Cipher Pharmaceuticals Q4 2019 Conference Call\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; BORDER-BOTTOM:black 0pt; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prngen3{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnbcc{\nBORDER-TOP:0pt solid; BORDER-RIGHT:0pt solid; BORDER-COLLAPSE: COLLAPSE; BORDER-BOTTOM:0pt solid; BORDER-LEFT:0pt solid\n}\n\n\n\n\n\n\n\nCanada NewsWire\nOAKVILLE, ON, Feb. 20, 2020\n\n\n\nOAKVILLE, ON, Feb. 20, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) (\"Cipher\" or \"the Company\") today announced the details of its Q4 2020 financial results conference call on Thursday, March 26, 2019. \nCONFERENCE CALL DETAILS\nDATE:            \nThursday, March 26, 2020\nTIME:              \n8:30 a.m. EDT\nDIAL IN NUMBER:       \n(416) 764-8688 or (888) 390-0546\nCONFERENCE ID:         \n02880904\nREPLAY:                    \n(888) 390-0541 (playback code 880904 #)\nAvailable until midnight April 2, 2020\nWEBCAST:                   \nThe audio webcast can be accessed at http://cipher.investorroom.com/ under Investor Relations or at https://event.on24.com/wcc/r/2203231/4C6EB61DB02BC18A6F5927498CF2787D\n \nAbout Cipher Pharmaceuticals Inc.Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets t...